NGL Fine Chem Ltd

NGLFINEPharmaceuticals
1677.30+0.00 (+0.00%)
As on 30 Jan 2026, 01:40 pmMarket Closed

Fundamental Score

...

NGL Fine Chem Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

7.75%
Poor

Return on Capital Employed

9.44%
Excellent

Operating Profit Margin (5Y)

17.42%
Poor

Dividend Yield

0.13%

Valuation Metrics

Poor

Price to Earnings

40.31x

Market Capitalization

833.93 (Cr)

Industry P/E

31.77x

Growth Metrics

Poor

YoY Quarterly Profit Growth

-1.83%
Excellent

YoY Quarterly Sales Growth

28.65%
Excellent

Sales Growth (5Y)

19.41%
Excellent

EPS Growth (5Y)

16.89%
Excellent

Profit Growth (5Y)

16.89%

Financial Health

Excellent

Debt to Equity

0.29x
Excellent

Interest Coverage

7.87x
Poor

Free Cash Flow (5Y)

-45.98 (Cr)

Ownership Structure

Good

Promoter Holding

72.74%
Poor

FII Holding

0.00%
Poor

DII Holding

0.00%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
72.74%
Promoter Holding
833.93 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of NGLFINE across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Operating Margins (17.42%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.

Strong Revenue Growth (28.65%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Consistent Growth Track Record (19.41% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.

Excellent EPS Growth (16.89% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.

Strong Profit Growth Track Record (16.89% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Conservative Debt Levels (D/E: 0.29)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (7.87x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Balanced Promoter Holding (72.74%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

5 factors identified

Below-Average Return on Equity (7.75%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (9.44%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.

Premium Valuation Risk (P/E: 40.31x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

Negative Free Cash Flow (₹-45.98 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Financial Statements

Comprehensive financial data for NGL Fine Chem Ltd

About NGLFINE

Business Overview

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Company Details

Symbol:NGLFINE
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Rahul Jayant Nachane ACA, B. Com, DBF, MMS
CEO, MD, Chief Ethics Counsellor & Executive Director
Mr. Rajesh Narayan Lawande
Whole Time Director & CFO
Ms. Pallavi Satish Pednekar
Company Secretary & Compliance Officer

Corporate Events

Recent
Ex-Dividend Date
2025-08-12

NGLFINE Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)7.75%
Return on Capital Employed9.44%
Operating Profit Margin (5Y)17.42%
Debt to Equity Ratio0.29
Interest Coverage Ratio7.87

Growth & Valuation

Sales Growth (5Y)19.41%
Profit Growth (5Y)16.89%
EPS Growth (5Y)16.89%
YoY Quarterly Profit Growth-1.83%
YoY Quarterly Sales Growth28.65%

Frequently Asked Questions

What is the current price of NGL Fine Chem Ltd (NGLFINE)?

As of 30 Jan 2026, 01:40 pm IST, NGL Fine Chem Ltd (NGLFINE) is currently trading at ₹1677.30. The stock has a market capitalization of ₹833.93 (Cr).

Is NGLFINE share price Overvalued or Undervalued?

NGLFINE is currently trading at a P/E ratio of 40.31x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.

What factors affect the NGL Fine Chem Ltd share price?

Key factors influencing NGLFINE's price include its quarterly earnings growth (Sales Growth: 28.65%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is NGL Fine Chem Ltd a good stock for long-term investment?

NGL Fine Chem Ltd shows a 5-year Profit Growth of 16.89% and an ROE of 7.75%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.29 before investing.

How does NGL Fine Chem Ltd compare with its industry peers?

NGL Fine Chem Ltd competes with major peers in the Pharmaceuticals. Investors should compare NGLFINE's P/E of 40.31x and ROE of 7.75% against the industry averages to determine its competitive standing.

What is the P/E ratio of NGLFINE and what does it mean?

NGLFINE has a P/E ratio of 40.31x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹40 for every ₹1 of annual earnings.

How is NGLFINE performing according to Bull Run's analysis?

NGLFINE has a Bull Run fundamental score of 49/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does NGLFINE belong to?

NGLFINE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting NGL Fine Chem Ltd.

What is Return on Equity (ROE) and why is it important for NGLFINE?

NGLFINE has an ROE of 7.75%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently NGL Fine Chem Ltd generates profits from shareholders' equity.

How is NGLFINE's debt-to-equity ratio and what does it indicate?

NGLFINE has a debt-to-equity ratio of 0.29, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is NGLFINE's dividend yield and is it a good dividend stock?

NGLFINE offers a dividend yield of 0.13%, which means you receive ₹0.13 annual dividend for every ₹100 invested.

How has NGLFINE grown over the past 5 years?

NGLFINE has achieved 5-year growth rates of: Sales Growth 19.41%, Profit Growth 16.89%, and EPS Growth 16.89%.

What is the promoter holding in NGLFINE and why does it matter?

Promoters hold 72.74% of NGLFINE shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is NGLFINE's market capitalization category?

NGLFINE has a market capitalization of ₹834 crores, placing it in the Small-cap category.

How volatile is NGLFINE stock?

NGLFINE has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for NGLFINE?

NGLFINE has a 52-week high of ₹N/A and low of ₹N/A.

What is NGLFINE's operating profit margin trend?

NGLFINE has a 5-year average Operating Profit Margin (OPM) of 17.42%, indicating the company's operational efficiency.

How is NGLFINE's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 28.65% and YoY Profit Growth of -1.83%.

What is the institutional holding pattern in NGLFINE?

NGLFINE has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.